Drug Approval | December 06, 2024
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination
For people with relapsed or refractory diffuse large B-cell lymphoma
For people with relapsed or refractory diffuse large B-cell lymphoma
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The workshop was conducted as a part of the NITI–State workshop series
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Mpower an initiative of Aditya Birla Education Trust works in the space of Mental health
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Advancing to IND-enabling studies with multiple drug candidates
Subscribe To Our Newsletter & Stay Updated
